In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
The novel β-lactam/β-lactamase inhibitor combinations (βL-βLICs) are one of the last-line resources available against multidrug-resistant (MDR) Gram-negative bacteria. Among βL-βLICs, ceftazidime/avibactam (CAZ-AVI) demonstrated strong activity against carbapenem-resistant <i>Enterobacterales&...
Saved in:
Main Authors: | Marta Palombo (Author), Benedetta Secci (Author), Federica Bovo (Author), Milo Gatti (Author), Simone Ambretti (Author), Paolo Gaibani (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against <i>KPC</i>-Producing <i>K. pneumoniae</i> Collected from Bacteremic Patients, 2018 to 2020
by: Federica Bovo, et al.
Published: (2022) -
Resistance to Ceftazidime/Avibactam in <i>Klebsiella pneumoniae</i> KPC-Producing Isolates: A Real-Life Observational Study
by: Laura Campogiani, et al.
Published: (2023) -
Ceftazidime-Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing <i>Klebsiella pneumoniae</i>
by: Li Ding, et al.
Published: (2022) -
The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023) -
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
by: Paolo Gaibani, et al.
Published: (2022)